醫療團隊
專業的醫護人員,提供最佳的醫療服務
醫師介紹
邱紹銘醫師
診斷性超音波、內視鏡診斷及治療、消化系統疾病診斷及治療
- 國語,英語,閩南語
醫師資歷
-
現職
- 高雄長庚紀念醫院 胃腸肝膽科系助理教授級主治醫師(2024.07)
- 高雄長庚紀念醫院 胃腸肝膽科系講師級主治醫師(2022.07)
- 高雄長庚紀念醫院 胃腸肝膽科系主治醫師 (2020.09~迄今)
-
學歷
- 長庚大學醫學系畢業(201406)
-
經歷
- 支援旗山醫院 (2023.01~2023.12)
- 高雄長庚紀念醫院 實習醫師 (201306-201405)
- 高雄長庚紀念醫院 畢業後一般醫學訓練 (201408-201505)
- 高雄長庚紀念醫院 內科部住院醫師 (201509-201808)
- 高雄長庚紀念醫院 胃腸肝膽科系住院醫師/總醫師 (201809-202008)
- 鳳山醫院 胃腸肝膽科主治醫師 (2021.01~2021.04)
- 雲林醫院 胃腸肝膽科主治醫師 (2021.05~2021.12)
-
學會與認證
- 台灣內科醫學會 會員及專科醫師
- 台灣消化系醫學會 會員及專科醫師
- 台灣消化系內視鏡醫學會 會員及專科醫師
-
論文及期刊發表
- Sonneveld MJ, Chiu SM(Co first), Park JY, Brakenhoff SM, Kaewdech A, Seto WK, Tanaka Y, Carey I, Papatheodoridi M, Colombatto P, van Bommel F, Janssen HL, Berg T, Zoulim F, ....., Chen CH*, Maasoumy B*, CREATE Study Group. Hepatitis B Virus DNA and Hepatitis B e Antigen Levels at 24 Weeks Off-Treatment Predict Clinical Relapse and Hepatitis B Antigen Loss in Hepatitis B e Antigen-Negative Patients Who Discontinued Antiviral Therapy. Gastroenterology. 2024 Jan; 166(1):168-177.e8. (SCI)
B型肝炎e抗原陰性病人停止抗病毒藥物後第24週的B型肝炎B型肝炎病毒量和表面抗原定量可以預測停藥後臨床復發和表面抗原消失 - Sonneveld MJ, Chiu SM(co-first), Park JY, Brakenhoff SM, Kaewdech A, Seto WK, Tanaka Y, Carey I, Papatheodoridi M, Colombatto P, van Bommel F, Berg T, Zoulim F, Hoon Ahn S, Dalekos GN, .......,Chen CH*, Maasoumy B*. CREATE study group Affiliations expnd. Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-negative chronic hepatitis B: A multicentre cohort study. JHEP Rep. 2023 Aug ;5(8):100790. (SCI)
B型肝炎e抗原陰姓病人治療前較低的B型肝炎病毒量有較好的停止核甘酸類似物的預後 - Chiu SM, Chang KC, Hu TH, Hung CH, Wang JH, Lu SN, Chen CH*. Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation. Dig Dis Sci. 2023 Feb;68(2):665-675. (SCI)
韋立得、貝樂克和惠立妥對於貝樂克和惠立妥停藥後病人治療及再治療的療效和腎功能安全性的比較 - Sonneveld MJ*, Chiu SM(co-first), Park JY, Brakenhoff SM, Kaewdech A, Seto WK, Tanaka Y, Carey I, Papatheodoridi M, van Bommel F, Berg T, Zoulim F, Ahn SH, Dalekos GN, Erler NS, Honer Zu Siederdissen C, Wedemeyer H, Cornberg M, Yuen MF, Agarwal K, Boonstra A, Buti M, Piratvisuth T, Papatheodoridis G, Chen CH*, Maasoumy B; Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels. CREATE study group. J Hepatol. 2022 May;76(5):1042-1050. (SC
停藥後依B型肝炎基因型和抗原來評估B型肝炎表面抗原消失的可能性 - Lai WT#, Chiu SM#, Wu CK, Liang CM, Yang SH, Yao CC, Kuo CM, Lu LS*, Chiu YC, Wu KL, Tai WC, Chuah SK*. Incidence of interval colorectal cancer: A tertiary hospital report. Adv Dig Med. 2021 Sept.; 8(3): 172-177. (台灣消化醫學雜誌)
南臺灣間隔性大腸直腸癌之發生率及危險因子 - Chiu SM, Kuo YH, Wang JH, Hung CH, Hu TH, Lu SN, Chen CH*. Associations of HBV Genotype B vs C Infection With Relapse After Cessation of Entecavir or Tenofovir therapy. Clin Gastroenterol Hepatol. 2020 Dec;18(13):2989-2997.e3. (SCI)
B型肝炎基因型B和C感染在貝樂克和惠立妥停藥後病毒復發的相關性
(長庚醫院2020年度住院醫師優良論文獎第二名) - Chiu SM, Tsai MC, Lin CY*, Chen CH, Lu SN, Hung CH, Sheen IS, Chien RN, Lin CL, Hu TH*, Cheng YF, Chen CL. Serial changes of renal function after directly acting antivirals treatment for chronic hepatitis C: A 1-year follow-up study after treatment. PLoS One. 2020 Apr 14;15(4):e0231102. (SCI)
慢性C型肝炎病人在直接抗病毒藥物治療後之一年腎功能變化
- Sonneveld MJ, Chiu SM(Co first), Park JY, Brakenhoff SM, Kaewdech A, Seto WK, Tanaka Y, Carey I, Papatheodoridi M, Colombatto P, van Bommel F, Janssen HL, Berg T, Zoulim F, ....., Chen CH*, Maasoumy B*, CREATE Study Group. Hepatitis B Virus DNA and Hepatitis B e Antigen Levels at 24 Weeks Off-Treatment Predict Clinical Relapse and Hepatitis B Antigen Loss in Hepatitis B e Antigen-Negative Patients Who Discontinued Antiviral Therapy. Gastroenterology. 2024 Jan; 166(1):168-177.e8. (SCI)